Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
| Preferred Name | Ambrisentan | |
| Synonyms |
|
|
| Definitions |
An orally bioavailable, selective antagonist of the endothelin type-A (ETA) receptor that may be used for the treatment of pulmonary arterial hypertension (PAH). Upon administration, ambrisentan targets and binds to ETA receptor, which prevents the binding of endothelin-1 (ET-1) to the ETA receptor and ET-1/ETA-mediated vasoconstriction and cell proliferation. This may lead to vasodilation. ET-1 concentrations are increased in plasma as well as lung tissue in PAH, and ET-1 may play a key role in the pathogenesis of PAH. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C72694 |
|
| CAS_Registry |
177036-94-1
|
|
| Chemical_Formula |
C22H22N2O4
|
|
| code |
C72694
|
|
| Contributing_Source |
FDA
|
|
| definition |
An orally bioavailable, selective antagonist of the endothelin type-A (ETA) receptor that may be used for the treatment of pulmonary arterial hypertension (PAH). Upon administration, ambrisentan targets and binds to ETA receptor, which prevents the binding of endothelin-1 (ET-1) to the ETA receptor and ET-1/ETA-mediated vasoconstriction and cell proliferation. This may lead to vasodilation. ET-1 concentrations are increased in plasma as well as lung tissue in PAH, and ET-1 may play a key role in the pathogenesis of PAH.
|
|
| FDA_UNII_Code |
HW6NV07QEC
|
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 |
|
| label |
Ambrisentan
|
|
| Legacy Concept Name |
Ambrisentan
|
|
| Preferred_Name |
Ambrisentan
|
|
| prefixIRI |
NCIT:C72694
|
|
| prefLabel |
Ambrisentan
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C1176329
|
|
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping